BioNTech Terminates Phase 2 Trial Of Autogene Cevumeran In Colorectal Cancer

BioNTech terminated its Phase 2 BNT122-01 trial evaluating autogene cevumeran as an adjuvant monotherapy in ctDNA-positive, surgically resected patients. The decision is a negative clinical development that increases uncertainty around near-term efficacy prospects for this program. Overall, the news is likely to pressure sentiment toward BNTX but is not expected to be broadly market-moving.